Novonesis A/S

Novonesis A/S is a global leader in biosolutions, formed in January 2024 through the merger of Novozymes and Chr. Hansen. Headquartered in Copenhagen, Denmark, the company's mission is to pioneer biological solutions that transform industries and address global sustainability challenges, leveraging the power of biology to improve how the world produces, consumes, and lives.

Novonesis offers a broad portfolio of enzymes, probiotics, cultures, proteins, and human milk oligosaccharides (HMOs). These biosolutions serve over 30 industries, categorized into two main divisions: "Healthier Lives" (Food & Health Biosolutions) and "Healthier Planet" (Planetary Health Biosolutions). Key market segments include food and beverage, human health, agriculture, household care, bioenergy, biopharma, and various industrial applications such as textiles and wastewater treatment.

Since its formation, Novonesis has quickly established a commanding market position, holding a significant share in both industrial enzymes and microbial solutions. The company reported strong financial performance with 8% organic sales growth in 2024 and 11% in Q1 2025. Recent developments include the launch of Bovacillus, a Bacillus probiotic for lactating dairy cows in Europe, and the acquisition of a production facility in Rayong, Thailand, to expand its global footprint and support HMO production. Ester Baiget serves as the President and CEO, leading the company's strategic direction.